<p>&nbsp;</p> <p align="justify">The competitiveness cluster <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/lyon-biopole-pole-centre-recherche-scientifique/index,p,98,EN.jsp" target="_blank">Lyonbiop&#244;le</a>, with over 30% of its projects certified in the field of cancer, and <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/cancerologie/index,p,164,EN.jsp" target="_blank">CLARA </a>(Canc&#233;rop&#244;le Lyon Auvergne Rh&#244;ne-Alpes), will pool their resources to <strong><em>&#8220;improve the transfer of knowledge derived from research for use in clinical applications and products.&#8221;</em></strong> Within the next six months, Canc&#233;rop&#244;le will leave its premises on Avenue Rockefeller to join Lyonbiop&#244;le in the Domilyon building, at the heart of the <a title="" style="color: rgb(224, 32, 32);" href="https://www.aderly.com/centre-recherche-et/developpement-france,p,21,EN.jsp" target="_blank">Lyon-Gerland biotech business park</a>. While maintaining their specific funding for calls for projects, the two organizations will implement unified procedures based on those of Lyonbiop&#244;le for certifying projects prior to submission in partnership with industrial companies. </p> <p align="justify"><br>This will effectively create a <strong>one-stop contact for companies and researchers developing projects</strong>. Measures will be taken to <em>&#8220;ensure the recognition of the community of oncology researchers and clinicians,&#8221;</em> explain the partners, who are also hoping to achieve &#8220;a clearer positioning of the health sector in the Rh&#244;ne-Alpes and Auvergne region as a European pioneer in the fight against infectious diseases in humans and animals and the fight against cancer, in order to open a wider range of possibilities for project financing.&#8221; <br></p> <p align="justify"><br></p>